Rabeprazole for the Prevention of Pathologic and Symptomatic Relapse of Erosive or Ulcerative Gastroesophageal Reflux Disease

Caos, Antonio; Moskovitz, Morry; Dayal, Yogeshwar; Perdomo, Carlos; Niecestro, Robert; Barth, Jay
November 2000
American Journal of Gastroenterology;Nov2000, Vol. 95 Issue 11, p3081
Academic Journal
OBJECTIVE: We evaluated the effectiveness and safety profile of 10 and 20 mg of rabeprazole, a new proton pump inhibitor, once daily versus placebo in preventing endoscopic and symptomatic relapse for up to 1 yr among patients with healed erosive or ulcerative gastroesophageal reflux disease (GERD). METHODS: The 52-wk trial used a multicenter, randomized, double-blind, parallel-group design in which 209 men and women were assigned to 10 or 20 mg of rabeprazole once daily in the morning or placebo. RESULTS: Both rabeprazole doses were significantly superior to placebo in preventing endoscopic relapse (p < 0.001), and 20 mg was significantly more effective than 10 mg (p < 0.04). Both doses were also significantly superior to placebo in reducing the frequency and severity of heart-burn relapse (p < 0.001). When adjusted for differences in exposure to study medication, no significant differences were found in the incidence of adverse events. No clinically significant changes were found regarding clinical laboratory parameters, vital signs, electrocardiograms, ophthalmological evaluations, body weight, serum gastrin, and enterochro-maffin-like cell histology. CONCLUSIONS: Once-daily therapy with 10 or 20 mg of rabeprazole effectively prevents pathological and symptomatic GERD relapse. The 20-mg dose is significantly more effective than the 10-mg dose in preventing endoscopic recurrence. Treatment was well tolerated, and no clinically signiticant safety findings emerged. Our findings support rabeprazole's efficacy in preventing GERD recurrence with excellent tolerability and a short-term favorable safety profile.


Related Articles

  • Review: On-demand maintenance therapy with proton pump inhibitors is as effective as continuous therapy for nonerosive GERD.  // ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p69 

    The article focuses on a clinical study analyzing the effectiveness of on-demand maintenance therapy with proton pump inhibitors (PPIs) in treating patients with gastroesophageal reflux disease (GERD). It discusses the methods followed, data sources, patients' selection criteria and the...

  • Arbaclofen Placarbil in GERD: A Randomized, Double-Blind, Placebo-Controlled Study. Vakil, Nimish B.; Huff, F. Jacob; Bian, Amy; Jones, Drew S.; Stamler, David // American Journal of Gastroenterology;Aug2011, Vol. 106 Issue 8, p1427 

    OBJECTIVES:It has been shown that arbaclofen placarbil (AP) inhibits reflux in gastroesophageal reflux disease (GERD) following single oral dosing. This study evaluated the efficacy and safety of AP over 4 weeks in subjects with symptomatic GERD.METHODS:One hundred fifty-six subjects with...

  • Xenoport's GERD Phase IIb Data Give Investors Heartburn. Shaffer, Catherine // BioWorld Today;3/22/2011, Vol. 22 Issue 55, p1 

    The article discusses the performance of Xenoport Inc.'s arbaclofen placarbil, the company's indication for gastroesophageal reflux (GERD), versus placebo in a Phase llb trial. Subjects with GERD symptoms were observed while being treated with proton pump inhibitor (PPI). The study showed...

  • A Placebo-Controlled Dose-Ranging Study of Lansoprazole in the Management of Reflux Esophagitis. Earnest, David L.; Dorsch, Ernst; Jones, James; Jennings, Dennis E.; Greski-Rose, Pamela A. // American Journal of Gastroenterology;Feb1998, Vol. 93 Issue 2, p238 

    Objective: We compared the efficacy of three different doses of the proton pump inhibitor lansoprazole in the management of reflux esophagitis. Methods: Two hundred ninety-two patients with endoscopically confirmed reflux esophagitis were enrolled in a double-blind, multicenter study and were...

  • Lansoprazole in Globus Pharyngeus: Double-Blind, Randomized, Placebo-Controlled Trial. Dumper, Jaymi; Mechor, Brad; Chau, Jason; Allegretto, Michael // Journal of Otolaryngology -- Head & Neck Surgery;Oct2008, Vol. 37 Issue 5, p657 

    Objective: To evaluate the effectiveness of once-daily lansoprazole in the typical globus pharyngeus patient, who presents with a normal head and neck examination and without other sinister otolaryngologic complaints. Study Design: Prospective, randomized, double-blind, placebo-controlled trial....

  • Research Brief: PPIs could help treat GORD.  // GP: General Practitioner;7/22/2005, p6 

    The article discusses the use of proton pump inhibitors (PPIs) for testing gastro-oesophageal reflux disease (GORD) in patients with non-cardiac chest pain. Researchers carried out a meta-analysis of six randomized, placebo-controlled trials that included 220 patients with non-cardiac chest...

  • Esomeprazole does not improve asthma control. Alagaratnam, J. // Thorax;Oct2009, Vol. 64 Issue 10, p915 

    The article focuses on a randomized study which evaluates whether the addition of proton pump inhibitors in gastro-oesophageal reflux disease may improve symptoms of asthma. In this study, 412 patients with asthma are randomized to receive either esomeprazole or placebo while continuing their...

  • Picking a PPI: It comes down to cost. Wigle, Patricia R.; Hein, Brad; Ellis, Robert; Austin, Orson; Kiesler, Joseph; Gait, Kimberly A. // Journal of Family Practice;Apr2008, Vol. 57 Issue 4, p231 

    The article offers tips in choosing the right proton pump inhibitor (PPI) for patients with heartburn in the U.S. A 33-year-old man complained about the occurrence of heartburns after he attempted to lose weight and try to exercise to manage his hypertension. To address the problem, it is...

  • Latest research on GORD.  // Update;10/20/2005, Vol. 71 Issue 4, p22 

    This article presents information on various research related to gastro-oesophageal reflux disease (GORD). One of the researches describes that proton-pump inhibitors (PPI) are best for preventing relapse. In endoscopically confirmed GORD, proton pump inhibitors comfortably outperform other...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics